December 24, 2020 — Among patients with Parkinson disease (PD), a positive history of essential tremor (ET) was found to be associated with slower progression of motor and nonmotor symptoms, with no impact observed on survival, according to study findings published in Scientific Reports.
CAMBRIDGE, Mass., December 17, 2020 – Cadent Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced today that it has reached a definitive agreement with Novartis, under which Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics. […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
BURLINGAME, Calif.–(BUSINESS WIRE)–Cala Health, Inc., a bioelectronic medicine company developing wearable therapies for chronic disease, today reported data demonstrating the increasing prevalence of essential tremor (ET) from 2010 to 2018; a high rate of depression and anxiety in patients with ET; and the safety and efficacy of Cala Trio when used in a real-world setting […]
The COVID-19 pandemic has posed new challenges for people living with movement disorders. In a brief survey of 130 patients, the Movement Disorders Policy Coalition explored the scope of the pandemic’s impact as well as the role of telemedicine in bridging the gaps in care.
A high-tech imaging study to understand how brain connectivity patterns change after deep brain stimulation in patients suffering from essential tremor has been launched at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial, led by Albert J. Fenoy, MD, associate professor of neurosurgery with McGovern Medical School at UTHealth, is funded […]
IETF Medical Advisory Board member Dr. Sheng-Han Kuo has been named a recipient of the The Derek Denny-Brown Young Neurological Scholar Award in Clinical Science from the American Neurological Association (ANA). Dr. Kuo is assistant director of neurology at Columbia University in New York City.
Bioelectronic company Cala Health released positive data from its ongoing PROSPECT trial demonstrating that a majority of patients using its FDA-cleared Cala Trio device reported a reduction in hand tremors.
ABBOTT PARK, Ill., July 23, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of the company’s Patient Controller app on compatible personal Apple‡ smartphone devices.